Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review

• Published in: Medicine (Baltimore) 2023-06, Vol.102 (23), p.e33874-e33874
• Main Authors: Rhyne, Christopher, Cohen, Joshua M, Seminerio, Michael J, Carr, Karen, Krasenbaum, Lynda J
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Calcitonin Gene-Related Peptide; Headache - drug therapy; Humans; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Narrative Review; Prescription Drug Overuse; Quality of Life
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000033874

Migraine is a complex and often debilitating neurological disease that affects more than 1 billion people worldwide. It is characterized by moderate-to-intense, throbbing headache attacks that are worsened by activity and is associated with nausea, vomiting, and sensitivity to light and sound. Migraine, ranked the second leading cause of years lived with disability by the World Health Organization, can diminish patients' quality of life and bring significant personal and economic burden. Furthermore, migraine patients with a history of acute medication overuse (AMO) or psychiatric comorbidities, such as depression or anxiety, may experience even greater impairment and burden, and their migraine may be more difficult-to-treat. Appropriate treatment of migraine is essential to reduce this burden and improve patient outcomes, especially for those with AMO or psychiatric comorbidities. There are several available preventive treatment options for migraine, though many of these are not migraine-specific and may have limited efficacy and/or poor tolerability. The calcitonin gene-related peptide pathway plays a key role in the pathophysiology of migraine, and monoclonal antibodies that target the calcitonin gene-related peptide pathway have been developed as specific preventive treatments for migraine. Four of these monoclonal antibodies have been approved for the preventive treatment of migraine after demonstrating favorable safety and efficacy profiles. These treatments offer substantial benefits for migraine patients, including those with AMO or common psychiatric comorbidities, by reducing monthly headache days and migraine days, days of acute medication use, and disability measures, as well as improving quality of life.